GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Debt-to-Equity

NKGen Biotech (NKGen Biotech) Debt-to-Equity : -0.40 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Debt-to-Equity?

NKGen Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $11.72 Mil. NKGen Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $10.50 Mil. NKGen Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-55.06 Mil. NKGen Biotech's debt to equity for the quarter that ended in Mar. 2024 was -0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NKGen Biotech's Debt-to-Equity or its related term are showing as below:

NKGN' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.37   Med: -0.4   Max: 7.7
Current: -0.4

During the past 3 years, the highest Debt-to-Equity Ratio of NKGen Biotech was 7.70. The lowest was -1.37. And the median was -0.40.

NKGN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs NKGN: -0.40

NKGen Biotech Debt-to-Equity Historical Data

The historical data trend for NKGen Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Debt-to-Equity Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Equity
-1.37 7.70 -0.34

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial 7.70 N/A -0.49 -0.34 -0.40

Competitive Comparison of NKGen Biotech's Debt-to-Equity

For the Biotechnology subindustry, NKGen Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Debt-to-Equity falls into.


NKGen Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NKGen Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(9.991 + 9.93) / -58.693
=-0.34

NKGen Biotech's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(11.719 + 10.495) / -55.055
=-0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech  (NAS:NKGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NKGen Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Debt-to-Equity
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.